Cipla Ltd

Cipla Employee Stock Options

Cipla allotted 44,770 equity shares following the exercise of employee stock options. This increases the company's total paid-up capital to over ₹161.56 Crore.

Cipla Annual Report

Cipla Limited has dispatched its Integrated Annual Report for FY 2025-26. The 90th Annual General Meeting is scheduled for June 25, 2026, via video conferencing.

Cipla Other Announcement

Cipla Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report by BNP & Associates confirms broad regulatory compliance.

Cipla Employee Stock Options

Cipla Ltd allotted 17,915 equity shares under its employee stock option and appreciation rights schemes. This marginally increases the company's total paid-up share capital.

Cipla Management Change

Cipla appointed Sushrut Kulkarni as President and Global Chief of Integrated Product Development. The firm also appointed Joshi Apte & Associates as new Cost Auditors.

Execution

12 months (Cost Auditor term)

Cipla Dividend

Cipla Limited recommended a final dividend of ₹13 per equity share for FY 2025-26. Shareholders as of the June 5, 2026 record date remain eligible.

Cipla Board Meeting Outcome

Cipla's board approved the 90th AGM for June 25, 2026, and appointed Sushrut Kulkarni as President. They also authorized grants under employee stock schemes.

Cipla Earnings Call: Key Takeaways

Cipla delivered highest-ever yearly revenue of ₹28,163 Cr in FY26, despite multiple headwinds. Strategy focuses on India growth, US pipeline expansion, and ESG goals.

Cipla Results Update

Cipla Limited reported record annual revenue of ₹28,163 Crore for FY26. The company declared a ₹13 per share dividend following robust double-digit growth in India.

Value

₹28,163 Cr

Cipla Q4 FY26 Results: Net Profit ₹542.5 Cr, Down 55.3% YoY

Cipla Ltd reported revenue from operations of ₹6,541 Cr (-2.8% YoY) and net profit of ₹542.5 Cr (-55.3% YoY) for Q4 FY26.

Key figure

Net profit ₹542.5 Cr · -55.3% YoY

Cipla Financial Results

Cipla announced audited FY26 financial results and recommended a final dividend of ₹13 per equity share. The results showcase annual performance alongside returns to shareholders.

Cipla Regulatory Approval

Cipla's US subsidiary received final USFDA approval for the first AB-rated generic therapeutic equivalent of Ventolin HFA. The Albuterol Sulfate Inhalation Aerosol is expected to launch in H1 FY 2026-27, targeting a US market valued at $1.5 billion.

Cipla Regulatory Approval

Cipla Limited announced the conclusion of a routine cGMP and Pre-Approval Inspection by the USFDA at its Goa facility. The inspection, conducted from April 6-17, 2026, resulted in two inspectional observations in Form 483. The company is committed to addressing these observations within the stipulated timeframe.

Cipla Q3 FY26 Results: Net Profit ₹674 Cr, Down 57.2% YoY

Cipla Ltd reported net profit of ₹674 Cr (-57.2% YoY) for Q3 FY26.

Key figure

Net profit ₹674 Cr · -57.2% YoY